159 related articles for article (PubMed ID: 37119666)
1. Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy.
Chen S; Chen Z; Lu L; Zhao Y; Zhou R; Xie Q; Shu Y; Lin J; Yu X; Wang Y
Eur J Med Chem; 2023 Jul; 255():115403. PubMed ID: 37119666
[TBL] [Abstract][Full Text] [Related]
2. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel BTK PROTACs for B-Cell lymphomas.
Zhao Y; Shu Y; Lin J; Chen Z; Xie Q; Bao Y; Lu L; Sun N; Wang Y
Eur J Med Chem; 2021 Dec; 225():113820. PubMed ID: 34509879
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Ibrutinib-based BTK PROTACs with in vivo anti-inflammatory efficacy by inhibiting NF-κB activation.
Huang J; Ma Z; Yang Z; He Z; Bao J; Peng X; Liu Y; Chen T; Cai S; Chen J; Zeng Z
Eur J Med Chem; 2023 Nov; 259():115664. PubMed ID: 37487306
[TBL] [Abstract][Full Text] [Related]
5. Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models.
Lim YS; Yoo SM; Patil V; Kim HW; Kim HH; Suh B; Park JY; Jeong NR; Park CH; Ryu JH; Lee BH; Kim P; Lee SH
Blood Adv; 2023 Jan; 7(1):92-105. PubMed ID: 36269842
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Bruton's Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy.
Li YQ; Lannigan WG; Davoodi S; Daryaee F; Corrionero A; Alfonso P; Rodriguez-Santamaria JA; Wang N; Haley JD; Tonge PJ
J Med Chem; 2023 Jun; 66(11):7454-7474. PubMed ID: 37195170
[TBL] [Abstract][Full Text] [Related]
7. Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.
Zhang J; Che J; Luo X; Wu M; Kan W; Jin Y; Wang H; Pang A; Li C; Huang W; Zeng S; Zhuang W; Wu Y; Xu Y; Zhou Y; Li J; Dong X
J Med Chem; 2022 Jul; 65(13):9096-9125. PubMed ID: 35671249
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases.
Huang J; Ma Z; Peng X; Yang Z; Wu Y; Zhong G; Ouyang T; Chen Z; Liu Y; Wang Q; Chen J; Chen T; Zeng Z
J Med Chem; 2024 Feb; 67(4):2438-2465. PubMed ID: 38321747
[TBL] [Abstract][Full Text] [Related]
9. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.
Jaime-Figueroa S; Buhimschi AD; Toure M; Hines J; Crews CM
Bioorg Med Chem Lett; 2020 Feb; 30(3):126877. PubMed ID: 31879210
[TBL] [Abstract][Full Text] [Related]
11. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
Das D; Wang J; Hong J
Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919
[TBL] [Abstract][Full Text] [Related]
12. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
13. PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding.
Tinworth CP; Lithgow H; Dittus L; Bassi ZI; Hughes SE; Muelbaier M; Dai H; Smith IED; Kerr WJ; Burley GA; Bantscheff M; Harling JD
ACS Chem Biol; 2019 Mar; 14(3):342-347. PubMed ID: 30807093
[TBL] [Abstract][Full Text] [Related]
14. Delineating the role of cooperativity in the design of potent PROTACs for BTK.
Zorba A; Nguyen C; Xu Y; Starr J; Borzilleri K; Smith J; Zhu H; Farley KA; Ding W; Schiemer J; Feng X; Chang JS; Uccello DP; Young JA; Garcia-Irrizary CN; Czabaniuk L; Schuff B; Oliver R; Montgomery J; Hayward MM; Coe J; Chen J; Niosi M; Luthra S; Shah JC; El-Kattan A; Qiu X; West GM; Noe MC; Shanmugasundaram V; Gilbert AM; Brown MF; Calabrese MF
Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7285-E7292. PubMed ID: 30012605
[TBL] [Abstract][Full Text] [Related]
15. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
16. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
17. Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.
Liu XJ; Xu-Liu ; Pang XJ; -Ying Yuan X; Yu GX; Li YR; Guan YF; Zhang YB; Song J; Zhang QR; Zhang SY
Bioorg Med Chem; 2021 Oct; 47():116358. PubMed ID: 34479103
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
Diao Y; Fang X; Song P; Lai M; Tong L; Hao Y; Dou D; Liu Y; Ding J; Zhao Z; Xie H; Li H
Bioorg Med Chem; 2019 Aug; 27(15):3390-3395. PubMed ID: 31221612
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
Ran F; Liu Y; Chen X; Zhuo H; Xu C; Li Y; Duan X; Zhao G
Bioorg Chem; 2021 Jul; 112():104968. PubMed ID: 34000704
[TBL] [Abstract][Full Text] [Related]
20. Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells.
Shorer Arbel Y; Katz BZ; Gabizon R; Shraga A; Bronstein Y; Kamdjou T; Globerson Levin A; Perry C; Avivi I; London N; Herishanu Y
Front Oncol; 2021; 11():646971. PubMed ID: 34055615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
